Ownership and insider activity for Immunic, Inc. (IMUX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease.
Price
| Price | $10.12 |
| Market Cap | $138M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-06 | Ridloff Elena | A-Award | 50,740 | $738K |
| 2026-08-06 | Ridloff Elena | |||
| 2026-07-05 | Skerjanec Simona | A-Award | 25,370 | $375K |
| 2026-07-05 | Rudick Richard Alan | A-Award | 25,370 | $375K |
| 2026-07-05 | PHILLIPS BARCLAY A | A-Award | 25,370 | $375K |
| 2026-07-05 | Neermann Joerg | A-Award | 25,370 | $375K |
| 2026-07-05 | Congleton Jon | A-Award | 25,370 | $375K |
| 2026-06-29 | Congleton Jon | A-Award | 50,740 | $553K |
| 2026-06-29 | Skerjanec Simona | A-Award | 25,370 | $277K |
| 2026-06-29 | Rudick Richard Alan | A-Award | 25,370 | $277K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $60.0M | $56.9M | $13.3M | $29.4M | $127.5M | $86.9M | $106.7M | $46.7M | $35.7M | $15.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $9.6M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $408000 | $295000 | $2.1M | $296000 | $703000 | $684000 | $4.1M |
| Inventory | 0 | 0 | -$191000 | -$408000 | 0 | 0 | $5.6M | 0 | 0 | 0 |
| Total Current Assets | $61.5M | $58.1M | $14.2M | $32.2M | $133.7M | $105.0M | $125.9M | $52.5M | $39.3M | $22.9M |
| Property, Plant & Equipment | $2.5M | $2.2M | $709000 | $713000 | $1.1M | $1.1M | $1.8M | $1.8M | $1.5M | $1.2M |
| Goodwill | 0 | 0 | 0 | $33.0M | $33.0M | $33.0M | 0 | 0 | 0 | 0 |
| Intangible Assets | $3.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $64.0M | $60.4M | $15.0M | $66.0M | $167.9M | $139.1M | $127.8M | $54.3M | $40.9M | $24.1M |
| Accounts Payable | $780000 | $1.0M | $268000 | $2.4M | $3.7M | $3.5M | $4.3M | $5.1M | $7.8M | $10.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $470000 |
| Total Current Liabilities | $5.5M | $10.3M | $2.5M | $7.1M | $8.4M | $11.4M | $13.1M | $24.7M | $22.2M | $30.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $107000 |
| Total Liabilities | $5.6M | $10.3M | $2.6M | $7.6M | $9.1M | $12.0M | $14.1M | $25.4M | $22.4M | $30.7M |
| Retained Earnings | -$243.8M | -$296.0M | -$337.4M | -$59.9M | -$103.9M | -$196.9M | -$317.3M | -$410.9M | -$511.4M | -$608.6M |
| Total Equity | $58.4M | $50.0M | $12.4M | $58.4M | $158.8M | $127.1M | $113.7M | $28.9M | $18.4M | -$6.7M |
| Total Debt | 0 | 0 | $37.2M | $520000 | $976000 | $992000 | $1.6M | $1.3M | $1.0M | $684000 |
| Net Debt | -$60.0M | -$56.9M | $23.9M | -$28.8M | -$126.5M | -$85.9M | -$114.8M | -$45.3M | -$34.7M | -$14.8M |
| Working Capital | $56.0M | $47.8M | $11.7M | $25.2M | $125.3M | $93.6M | $112.8M | $27.8M | $17.2M | -$7.7M |
Financial Health
| Debt / Equity | -0.10 |
| Current Ratio | 0.75 |
Profitability
| Return on Equity | 1456.20% |
| Return on Invested Capital | 1693.37% |
| Return on Assets | -404.01% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ACRV · BMEA · CBUS · LITS · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of IMUX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks